Clinical Trial Update: Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD [Phase 2]

View source ↗

Summary

A Phase 2 study of apitegromab for facioscapulohumeral muscular dystrophy (FSHD) is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facioscapulohumeral Muscular Dystrophy

Drugs mentioned

• Apitegromab (SRK-015)

Snippet

Sponsor: Scholar Rock, Inc. | Conditions: Facioscapulohumeral Muscular Dystrophy, FSHD | Phase 2 | Status: NOT_YET_RECRUITING